Ruhenstroth-Bauer, G.; Wünsch, E.; Valet, G.; Moroder, L. 1,4-Diacetoxy-2,3-dicyanobenzene, 1,4-dibutyryloxy-2,3-dicyanobenzene, 1,4-di(tert-butyloxycarbonyl-1-alanyloxy)2,3-dicyanobenzene and their use in determining the pH within a cell. Ger. Offen. (1982), DE 3104078 A1.

Valet, G.; Ruhenstroth-Bauer, G.; Wünsch, E.; Moroder, L. Compounds for determining the pH value in the interior of a cell. US Patent 4515730 (May 7, 1985)

Valet, G.; Ruhenstroth-Bauer, G.; Wünsch, E.; Moroder, L. Process for determining the pH value in the interior of Cell, US Patent 4677060 (June 30, 1987)

Wünsch, E.; Moroder, L. Hinge peptide, process for its manufacture, and its use for manufacture of synthetic immunogens. US Patent 5041533 (August 20, 1991)

Moroder, L.; Bode, W.; Grams, F.; Huber, R. Malonic acid based matrix metalloproteinase inhibitors. Eur. Pat. Appl.  (1996), EP 716086 A1; US Patent Application 2002/0049185 A1.

Moroder, L.; Bode, W.; Grams, F.; Huber, R. Preparation of (pseudo)malonic acid based matrix metalloproteinase inhibitors. PCT Int. Appl. (1996), WO 9617838 A1.

Müller, J. C. D.; Graf von Roedern, E.; Moroder, L. Preparation of cysteine derivatives and pharmaceuticals containing them. PCT Int. Appl. (1998), WO 9850351 A1.

Budisa, N.; Huber, R.; Minks, C.; Moroder, L. Incorporation of pharmacologically active amino acid analogs into proteins. PCT Int. Appl. (1998), WO 9856824 A2.

Grams, F.; Moroder, L.; Graf von Rodern, E. Malonic acid based matrix metalloproteinase inhibitors. PCT Int. Appl. (1999), WO 9911608 A1.

Bode, W.; Moroder, L.; Pereira, P. J. B.; Bergner, A.; Huber, R.; Sommerhoff, C.; Schaschke, N.; Bär, T.; Martin, T.; Stadlwieser, J.; Ulrich, W.-R.; Dominik, A.; Thibaut, U.; Bundschuh, D.; Beume, R.; Goebel, K.-J. Preparation of pyridinedicarboxylic acid bisacylpiperazides and related compounds as tryptase inhibitors. PCT Int. Appl. (1999), WO 9940073 A2.

Bode, W.; Moroder, L.; Pereira, P. J. B.; Bergner, A.; Huber, R.; Sommerhoff, C.; Schaschke, N.; Bär, T.; Martin, T.; Stadlwieser, J.; Ulrich, W.-R.; Dominik, A.; Thibaut, U.; Bundschuh, D.; Beume, R.; Goebel, K.-J. Preparation of pyridinedicarboxylic acid bisacylpiperazides and related compounds as tryptase inhibitors. PCT Int. Appl. (1999), WO 9940083 A2.

Bode, W.; Moroder, L.; Pereira, P. J. B.; Bergner, A.; Huber, R.; Sommerhoff, C.; Schaschke, N.; Bär, T.; Martin, T.; Stadlwieser, J.; Ulrich, W.-R.; Dominik, A.; Thibaut, U.; Bundschuh, D.; Beume, R.; Goebel, K.-J. Tryptase inhibitors. US Patent 6613769 (Sept. 2, 2003)

Ditzel, L.; Groll, M.; Huber, R.; Loidl, G.; Musiol, H.-J.; Moroder, L. Bivalent inhibitors of the proteasome. Eur. Pat. Appl. (2000), EP 982317 A1.

Eichinger, A.; Beisel, H.-G.; Bode, W.; Huber, R.; Moroder, L.; Travis, J.; Potempa, J.; Alefelder, S.; Pleiner, E.; Stürzebecher, J. Crystal structure of gingipain R and its complexes with inhibitors and applications to drug design and treatment of periodontal diseases. PCT Int. Appl. (2000), WO  2000071682 A2.

Schaschke, N.; Moroder, L.; Huber, R.; Bode, W.; Sommerhoff, C. Preparation of disubstituted 2,5-diketopiperazines derivatives for use as tryptase-inhibitor medicaments in the treatment of disease. PCT Int. Appl. (2001), WO 2001010845 A1.

Magdolen, V.; Moroder, L.; Sperl, S.; Stuerzebecher, J.; Wilhelm, O. Preparation of arylguanidines as selective inhibitors of urokinase plasminogen activator. PCT Int. Appl. (2001), WO 2001014324  A1.

Magdolen, V.; Moroder, L.; Sperl, S.; Stuerzebecher, J.; Wilhelm, O. Selective inhibitors of the urokinase plasminogen activator. US Patent 7049460 B1 (Aug. 24, 2006)

Moroder, L.; Sperl, S.; Stürzebecher, J. Synthesis of arginine mimetics as factor Xa inhibitors for use in anti-coagulation or antitumor therapy or as diagnostic material. PCT Int. Appl. (2001), WO  2001058859 A1.

Moroder, L.; Sperl, S.; Stürzebecher, J. Arginine mimetics as factor Xa inhibitors. US Patent 7038074 B2 (May 2, 2006).

Magdolen, V.; Sperl, S.; Stürzebecher, J.; Wilhelm, O.; Arroyo-Deprada, N.; Moroder, L.; Huber, R.; Jacob, U.; Bode, W. Highly selective arylguanidine inhibitors of urokinase plasminogen activator, preparation, and therapeutic use. PCT Int. Appl. (2001), WO 2001070204 A2.

Magdolen, V.; Sperl, S.; Stürzebecher, J.; Wilhelm, O.; Arroyo-Deprada, N.; Moroder, L.; Huber, R.; Jacob, U.; Bode, W. Highly selective arylguanidine inhibitors of the urokinase plasminogen activator, preparation, and therapeutic use. US Patent Application US 2005/0119348 A1.

Moroder, L.; Musiol, H.-J. Preparation of 1H-benzotriazole-1-carboxamidine derivatives and their use for the conversion of primary or secondary amines to diprotected guanidines. Ger. Offen.  (2002), DE 10057996 A1.

Huber, R.; Budisa, N.; Moroder, L.; Alefelder, S.; Bae, J. H.; Kaiser, J.; Freye-Minks, C.; Neuefeind, T. Preparation of sulfur-, selenium- or tellurium-containing or bromo- or iodo-substituted tryptophan analogs and their use in peptide or protein synthesis for improved spectral discrimination. Eur. Pat. Appl. (2002), EP 1219603 A2.

Groll, M.; Huber, R.; Kaiser, M.; Renner, C.; Moroder, L.; Kohno, J. Crystals of proteasome-inhibitor complex. PCT Int. Appl. (2002), WO 2002081501 A1.

Huber, R.; Sondermann, P.; Jacob, U.; Wendt, K.; Chiara, C.; Moroder, L. Immunogens comprising conformationally discriminating epitopes to produce Fcg RIIb- or Fcg RIIa-binding antibodies for diagnosis and therapy of neoplastic, infectious, immune and autoimmune diseases. PCT Int. Appl.  (2005), WO 2005051999 A2.

Huber, R.; Sondermann, P.; Jacob, U.; Wendt, K.; Chiara, C.; Moroder, L. Substance binding human Igg FC Receptor IIB (FCYRIIB). US Patent: US 08853363 (Oct 7, 2014).